Cyclacel Pharma (CYCC) Income Statement

Click line-items for a historical chart and %

Revenues:
Collaboration and research and development revenue
Product revenue
Grant revenue	205K
Total revenue	205K
Operating expenses:
Cost of goods sold
Research and development	2.41M
Selling, general and administrative	1.27M
Goodwill and intangibles impairment
Restructuring costs
Total operating expenses
Operating loss	-3.48M
Other income (expense):
Costs associated with aborted 2004 IPO
Payment under guarantee
Change in valuation of derivative
Change in valuation of warrants
Warrant re-pricing
Foreign exchange (losses)/gains	51K
Interest income	8K
Interest expense
Total other income (expense)	77K
Loss before taxes
Income tax benefit	454K
Net loss	-2.95M
Dividends on preferred ordinary shares
Deemed dividend on convertible exchangeable preferred shares
Dividend on convertible exchangeable preferred shares
Net loss applicable to common shareholders	-3M
Net loss per share- Basic and diluted
Weighted average common shares outstanding

Entities mentioned with CYCC